Skip to content
Research articles with safety and study context in view.
Your Peptide Tracker

Logging fresh findings for semaglutide, KPV, MOTS-c.

Menu

Semaglutide research and safety

Semaglutide has evidence from large studies in people, including trials that counted serious heart and kidney events. That makes it different from the early laboratory work discussed elsewhere on this site. It also makes the details important: the people enrolled, the medicine studied, and the outcome measured all affect what a finding means.

Semaglutide is the active ingredient in the FDA-approved brands Ozempic, Wegovy, and Rybelsus. Their approved uses and formulations differ. An ingredient name alone does not identify the right product, establish eligibility, or explain the warnings that apply to an individual.

Appetite and weight in STEP 1

A cropped side view of a person holding a fork above an ordinary lunch.

Semaglutide activates the receptor for GLP-1, a hormone involved in appetite and blood-sugar regulation. A receptor is a protein that receives a chemical signal. Effects on appetite help explain why weight is one of the main outcomes researchers follow.

The STEP 1 trial in adults without diabetes enrolled people with obesity, or overweight with a related health condition. STEP 1 reported average weight reductions of 14.9% for semaglutide and 2.4% for placebo at the 68-week assessment. Both groups received lifestyle support. Those figures describe group averages under study conditions; they do not forecast one person's result.

The comparison group matters. Weight changed in both groups, so the medicine's contribution is assessed against what happened with placebo. The follow-up period matters too: a measurement at the end of a trial cannot establish that a change will remain after treatment stops.

Heart and kidney outcomes

In SELECT, researchers counted major cardiovascular events among adults with established cardiovascular disease and overweight or obesity, without diabetes. Cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 6.5% of semaglutide participants and 8.0% of placebo participants. The absolute difference was 1.5 percentage points; the reported relative risk reduction was about 20%.

These were people with existing cardiovascular disease. The result cannot simply be extended to everyone seeking weight loss. It also describes a combined outcome, rather than proving that every component changed by the same amount.

The FLOW trial studied a separate kidney-risk population: adults with type 2 diabetes and chronic kidney disease. Semaglutide reduced a combined outcome involving kidney failure, substantial loss of kidney function, or kidney or cardiovascular death. FLOW supports a different clinical question from STEP 1, even though both studied semaglutide.

Safety alongside the benefits

A review of semaglutide safety describes nausea, vomiting, diarrhea, and constipation as important adverse effects. Digestive effects can lead people to stop treatment. Their frequency depends on the product, study population, and treatment setting; a single rate cannot stand for every use.

The Wegovy prescribing information also addresses gallbladder disease, pancreatitis, dehydration-related kidney injury, and worsening diabetic eye disease in some people with diabetes. Its boxed thyroid warning reflects findings in rodents; the relevance of those tumors to humans remains uncertain. Medical history and other medicines are part of a prescribing decision, beyond the outcomes summarized here.

Approved medicines and compounded preparations

Compounded preparations are not FDA-approved medicines. The evidence for a manufactured study medicine does not establish the quality, safety, or effectiveness of every preparation described as semaglutide. FDA also distinguishes the active ingredient used in approved drugs from semaglutide salt forms.

The agency's discussion of unapproved GLP-1 products explains concerns about dosing errors, ingredient differences, and product quality. These regulatory and formulation questions are separate from whether semaglutide helped participants in a particular trial. A publication about benefits cannot resolve them for an unfamiliar preparation.

Semaglutide prescription terms

Several terms describe different parts of a treatment conversation. Keeping their meanings separate helps when reading an article or discussing a request with a provider.

Prescribing review

An assessment of a person's health history, current medicines, treatment goals, and reasons a requested medicine might be unsuitable. Reading a research result does not replace that assessment.

Prescription service

For semaglutide, the telehealth option at Promise Peptides (mypromise.com) is open to patients in the United States only.

Study eligibility

The rules used to select research participants. They describe who a trial could evaluate, rather than providing a personal treatment recommendation. The comparison page explains why these boundaries change the meaning of a result.

Explore the sources